COA6-Related Fatal Infantile Cardioencephalomyopathy — Comprehensive Research Report

1. Disease Information

Overview: COA6-related fatal infantile cardioencephalomyopathy is an ultra-rare, autosomal recessive mitochondrial disease caused by biallelic pathogenic variants in COA6 (Cytochrome C Oxidase Assembly Factor 6). It belongs to the family of isolated mitochondrial complex IV (cytochrome c oxidase, COX) deficiencies and manifests in the neonatal period with severe hypertrophic cardiomyopathy (often with left ventricular non-compaction), lactic acidosis, and hypotonia, typically progressing to death within the first weeks of life (OMIM #616501).

Key identifiers: - OMIM disease entry: #616501 — Mitochondrial Complex IV Deficiency, Nuclear Type 13 (MC4DN13) - OMIM gene entry: 614772 — CYTOCHROME c OXIDASE ASSEMBLY FACTOR 6; COA6 - MONDO: MONDO:0014668 - Orphanet: The gene page Orphanet: COA6 links COA6 to "Fatal infantile cytochrome C oxidase deficiency" (ORPHA:1561), the broader clinical category shared with SCO2, COX15, and related genes - MedGen concept: related concepts include C3554534 ("Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2") — note that different databases (OMIM, MedGen, ClinVar) use slightly inconsistent numeric suffixes ("2" vs "4") for this entity across sources; curators should not over-interpret the exact ordinal without cross-checking the specific database version - HGNC: HGNC:18025 - Entrez/NCBI Gene ID: 388753 - Cytogenetic location: 1q42.2 (GRCh38 chr1:234,373,456–234,385,080) - Gene aliases: C1orf31*

Synonyms for the disease: Mitochondrial complex IV deficiency, nuclear type 13 (MC4DN13); COX deficiency due to COA6 mutation; COA6-related cardiomyopathy; cytochrome c oxidase deficiency, COA6-related.

Evidence basis: Nearly all clinical knowledge derives from two published index families (individual case reports with segregating genetics, functional cell/model validation) rather than large aggregated cohorts — this is a genuinely ultra-rare, single-gene Mendelian disorder with only a handful of molecularly confirmed patients in the literature.

2. Etiology

Primary cause: Biallelic (homozygous or compound heterozygous) loss-of-function pathogenic variants in COA6, which disrupt the copper-dependent biogenesis of mitochondrial complex IV subunit COX2 (MT-CO2), causing isolated complex IV (cytochrome c oxidase) deficiency.

Genetic risk factors: - Autosomal recessive inheritance — both parents are obligate heterozygous carriers, typically clinically unaffected. - Consanguinity is a documented risk factor: the second reported family (Baertling et al., 2015) involved "a female infant born of consanguineous parents of Arab descent" with a homozygous COA6 variant, illustrating the classic recessive-disease enrichment pattern in consanguineous unions. - No modifier genes have yet been identified, though functional work shows genetic/biochemical interaction with SCO1 and SCO2 (see Mechanism), raising the theoretical possibility that variation in these interacting genes could modulate phenotype severity, though this has not been demonstrated clinically.

Environmental/other risk factors: None established; this is a purely monogenic disorder with no known environmental, infectious, or lifestyle contribution to disease causation.

Protective factors: None specifically documented for COA6 deficiency. By analogy to the related disorder SCO2 deficiency, copper has been explored as a potential ameliorating cofactor at the cellular level (see Treatment/Mechanism sections), but this is a pharmacological/therapeutic avenue rather than a naturally occurring protective factor.

Gene-environment interactions: None reported. Disease penetrance and severity in the reported cases appear to be driven by variant type (truncating/null vs. specific missense) rather than by environmental modifiers.

3. Phenotypes

Cardiac phenotypes

• Hypertrophic cardiomyopathy — onset in the neonatal period (birth to first days of life), severe, biventricular. Described in both index families as the dominant and life-limiting feature.
• HPO: Hypertrophic cardiomyopathy (HP:0001639); Biventricular hypertrophy (HP:0001725) as applicable
• Left ventricular non-compaction — echocardiography in the Baertling et al. patient showed "severe hypertrophic cardiomyopathy affecting both ventricles with some areas of noncompaction in the left ventricle."
• HPO: Left ventricular noncompaction cardiomyopathy (HP:0006955)
• Valvular insufficiency — mitral, tricuspid, and pulmonic insufficiency reported on echocardiography.
• HPO: Mitral regurgitation (HP:0031628); Tricuspid regurgitation (HP:0025166); Pulmonic regurgitation (as applicable)
• Onset: congenital/neonatal, present at birth or emerging within the first days of life. Severity: severe, rapidly progressive, fatal.

Systemic/metabolic phenotypes

• Lactic acidosis — severe, appearing soon after birth in both families; a core biochemical hallmark of the mitochondrial respiratory chain defect.
• HPO: Lactic acidosis (HP:0003128)
• Hypothermia and tachypnea — reported in the neonatal presentation.
• HPO: Hypothermia (HP:0002045); Tachypnea (HP:0002789)
• Metabolic/muscular hypotonia — "muscular hypotonia" was described in the Baertling patient; systemic floppiness consistent with mitochondrial myopathy.
• HPO: Hypotonia (HP:0001252); Neonatal hypotonia (HP:0001319)
• Failure to thrive / weakness — general OMIM clinical synopsis notes "hypotonia, weakness, and failure to thrive, resulting in death in infancy."
• HPO: Failure to thrive (HP:0001508)

Neurologic/encephalopathic phenotypes ("encephalo-" component)

• Encephalopathic features are part of the disease name ("cardioencephalomyopathy"), reflecting CNS involvement alongside the cardiac and muscular phenotype, consistent with generalized mitochondrial energy failure affecting high-energy-demand tissues (brain, heart, skeletal muscle).
• HPO candidate terms: Encephalopathy (HP:0001298)

Other/dysmorphic

• Mild dysmorphic features and systolic murmur noted at birth in at least one patient.
• HPO: Systolic murmur (HP:0033553_or similar); dysmorphic features (nonspecific, general term)

Phenotype characteristics

• Age of onset: Neonatal (birth to first days of life) in both reported families — this is a uniformly neonatal-onset, not later-onset, disorder based on current literature.
• Severity: Uniformly severe/fatal in the reported cases; no attenuated or later-onset COA6 phenotype has yet been published (contrast with the related gene COX6B1 or milder complex IV deficiencies).
• Progression: Rapidly progressive — both index patients died in infancy/early weeks of life.
• Frequency among affected individuals: Because only two molecularly confirmed families have been published, frequency estimates for individual phenotypes (e.g., "X% have LVNC") cannot be reliably calculated; the phenotypes above were present in the majority/all of the very small number of reported cases.
• Quality of life impact: Given the fatal, rapidly progressive neonatal course, quality-of-life impact is profound but of very short duration (days to weeks); no structured QOL instrument data (EQ-5D, etc.) exist for this ultra-rare condition.

4. Genetic/Molecular Information

Causal gene: COA6 (HGNC:18025; Entrez Gene 388753; chromosome 1q42.2; OMIM *614772).

Reported pathogenic variants (both from the two founding case reports):

Variant classification: All reported disease-causing variants are classified as pathogenic per functional and segregation evidence (ACMG/AMP framework implied by ClinVar submissions), though formal multi-lab ClinVar consensus classification data for each variant were not independently retrieved in this search.

Allele frequency in population databases: COA6 is not listed among genes with notable population allele frequency data readily surfaced by general search; given the extreme rarity of the disease (only 2 published families) and the severity of the phenotype (fatal in infancy), pathogenic COA6 alleles are expected to be present at very low frequency in gnomAD, consistent with a severe recessive lethal disorder. Direct gnomAD constraint metrics (o/e, pLI) for COA6 were not confirmed in this search and should be verified directly at gnomad.broadinstitute.org before citation in a KB entry.

Somatic vs. germline: All reported variants are germline (inherited, biallelic); no somatic/postzygotic mosaic cases have been reported.

Functional consequences — loss of function is the unifying mechanism: - Both the W59C+E87X compound heterozygous genotype and the homozygous W66R genotype behave as loss-of-function alleles. - Functional/yeast complementation: mutant COA6 alleles "were unable to rescue mitochondrial respiratory growth defect in Coa6-null yeast, consistent with a loss of function" (functional_impact_category candidate: LOSS_OF_FUNCTION / PARTIAL_LOSS_OF_FUNCTION depending on variant). - The W59C variant specifically causes protein mistargeting — instead of localizing correctly to the mitochondrial intermembrane space, mutant COA6 is mistargeted to the mitochondrial matrix, disrupting its normal interactions with SCO2 and newly synthesized COX2 (a distinct, more complex loss-of-function mechanism beyond simple protein instability). - Patient fibroblasts (W66R) show complete absence of COA6 protein, consistent with a null/amorphic allele via nonsense-mediated decay or protein instability.

Modifier genes: None formally established in patients; however, cell-based studies show a direct biochemical/genetic interaction between COA6 and SCO2 — “Mitochondrial disease genes COA6, COX6B and SCO2 have overlapping roles in COX2 biogenesis” (PMID:26669719) and "Cooperation between COA6 and SCO2 in COX2 Maturation... Links Two Mitochondrial Cardiomyopathies" (Pacheu-Grau et al., 2015, Cell Metabolism 21:823-833, PMID:25959673), suggesting SCO2 variants could theoretically modify COA6-disease expressivity, though this is not clinically demonstrated.

Epigenetic information: No epigenetic (DNA methylation, histone modification) contribution to COA6-related disease has been reported; this is a straightforward loss-of-function Mendelian gene defect.

Chromosomal abnormalities: None reported; disease is caused by point mutations (missense, nonsense) rather than large structural/copy-number changes.

5. Environmental Information

No environmental factors, toxins, lifestyle exposures, or infectious triggers have been implicated in COA6-related disease causation or exacerbation. This is consistent with its status as a pure monogenic mitochondrial disorder. (Note for curation: given the KB's environmental-evidence discipline, this section should likely remain unpopulated or explicitly noted as "no evidence of environmental contribution identified in literature search" rather than speculatively populated.)

6. Mechanism / Pathophysiology

Ordered causal chain

1. Biallelic pathogenic COA6 variants (e.g., homozygous W66R, or compound heterozygous W59C/E87X) → loss of functional COA6 protein in the mitochondrial intermembrane space (via mistargeting, truncation, or instability/absence).
2. Loss of COA6 → failure of COA6's thiol-reductase/copper-relay function — COA6 normally acts as a thiol-disulfide oxidoreductase that reduces cysteine residues on COX2 and on the copper metallochaperone SCO1, enabling Cu(I) binding in the otherwise oxidizing intermembrane-space environment (PMID:32061935, J Mol Biol / Cell Reports structural studies).
3. This reductase failure → impaired copper (CuA site) metallation of newly synthesized COX2 (mtDNA-encoded core subunit of complex IV), because COA6 cooperates with SCO1 and SCO2 in a sequential copper-delivery pathway to the CuA binuclear copper center of COX2 (Pacheu-Grau et al. 2015, PMID:25959673; "COA6 interacts transiently with the copper-containing catalytic domain of newly synthesized COX2").
4. Failure of COX2 maturation → rapid proteolytic turnover of unassembled/unmetallated COX2 and accumulation of stalled complex IV assembly intermediates (involving the COX20–TMEM177–COA6 intermediate complex described by Soma et al. 2019, Cell Reports 29:4114-4126, PMID:31851937).
5. Loss of mature COX2 → failure of cytochrome c oxidase (complex IV) holoenzyme assembly, producing isolated (biochemically selective) complex IV deficiency on respiratory chain enzymology, demonstrated in patient fibroblasts and muscle.
6. Complex IV deficiency → impaired terminal electron transport and oxidative phosphorylation (OXPHOS), most severely affecting the highest-energy-demand postmitotic tissues: cardiomyocytes, neurons, and skeletal muscle.
7. In cardiomyocytes → energy failure drives compensatory/maladaptive hypertrophic remodeling and disordered myocardial compaction, producing the clinical hypertrophic cardiomyopathy and left ventricular non-compaction seen on echocardiography. (Inferred mechanistic step — the direct causal link from OXPHOS failure to LVNC morphogenesis is inferred from the general biology of energy-deficient cardiomyopathies rather than directly demonstrated for COA6 specifically.)
8. Systemically → impaired OXPHOS drives anaerobic glycolytic compensation, producing lactic acidosis, and generalized energy deficit in skeletal muscle and CNS produces hypotonia and encephalopathic features (the "encephalo-" component of cardioencephalomyopathy). (Inferred/generalized mitochondrial-disease mechanism, consistent with but not uniquely demonstrated for COA6.)
9. The combined burden of severe cardiac pump failure, systemic metabolic acidosis, and multi-organ energy failure in the neonatal period → early infantile death, typically within the first weeks of life.

Molecular pathway / process detail

• Pathway: Mitochondrial complex IV (cytochrome c oxidase) biogenesis / assembly pathway; copper-relay/metallochaperone pathway (SCO1–SCO2–COA6–COX2 axis); MIA40/ERV1 disulfide-relay mitochondrial intermembrane-space protein import pathway (COA6 is itself a substrate of this import machinery, oxidized/folded upon import via its twin CX9C motif).
• GO: mitochondrial respiratory chain complex IV assembly (GO:0033617); cytochrome complex assembly (GO:0017004); protein import into mitochondrial intermembrane space (GO:0045041); copper ion transport (GO:0006825)
• Cellular process: Failure of oxidative phosphorylation complex assembly; compensatory metabolic shift toward anaerobic glycolysis; likely activation of the mitochondrial unfolded protein/integrated stress response (not directly demonstrated for COA6 but general to severe OXPHOS defects).
• Protein structure/function: COA6 is a small (14.1 kDa, 125 amino acid) soluble mitochondrial intermembrane-space protein with a CX9CXnCX10C twin cysteine motif forming a coiled-coil-helix-coiled-coil-helix (CHCH) domain — a redox-active fold. It is imported and oxidatively folded by the MIA40 (CHCHD4)/ERV1(ALR) disulfide-relay pathway. Structural/biochemical studies characterize COA6 as a thiol-disulfide oxidoreductase (not a copper metallochaperone per se) that reduces cysteines on COX2 and SCO1 to permit copper loading (Bourens & Barrientos-type structural work; PMC6743065, PMC8773535, and the ScienceDirect papers on "COA6 Facilitates Cytochrome c Oxidase Biogenesis as Thiol-reductase" PMID:32061935, and "COA6 Is Structurally Tuned to Function as a Thiol-Disulfide Oxidoreductase").
• Metabolic changes: Reduced oxidative ATP generation; elevated blood lactate (glycolytic compensation); consistent with generalized mitochondrial energy metabolism failure rather than a specific isolated metabolite defect.
• Immune system involvement: None described; not an immune-mediated disease.
• Tissue damage mechanisms: Energy failure/ischemia-like injury in high-demand tissues (heart, brain, muscle) secondary to OXPHOS insufficiency, rather than classic oxidative-stress-driven fibrosis (though secondary oxidative stress from an inefficient/uncoupled respiratory chain is plausible and typical of complex IV disorders generally).
• Biochemical abnormality: Isolated cytochrome c oxidase (complex IV) enzymatic deficiency, demonstrated biochemically in patient fibroblasts/muscle, with normal or relatively preserved activity of complexes I, II, III, and V — the classic "isolated COX deficiency" biochemical signature that first directs genetic testing toward the COX-assembly-factor gene set (SURF1, SCO1, SCO2, COX10, COX15, COA5, COA6, COA7, etc.).

Molecular/cell-type involvement for annotation

• Cell types affected: cardiomyocyte (CL:0000746); skeletal myocyte; neuron (generalized)
• Subcellular localization (GO Cellular Component): mitochondrial intermembrane space (GO:0005758); mitochondrial inner membrane (associated, via interaction with COX2/COX20/TMEM177)

Molecular profiling / advanced technologies

• No transcriptomic, proteomic, or single-cell datasets specific to human COA6-deficient tissue were identified in this search (consistent with the extreme rarity of the disease and the reliance on classic biochemical/genetic case-report methodology plus model-organism validation).
• Model-system profiling that has been done: yeast complementation assays (Coa6-null yeast strain rescue experiments); zebrafish morphant (knockdown) assays with cardiac phenotyping; human patient fibroblast biochemical and immunoblot studies (complex IV activity, COA6/COX2/SCO1/SCO2 protein levels); in vitro biophysical/structural characterization of recombinant COA6 protein (NMR/crystallography-adjacent structural biology, e.g., Life Science Alliance 2019, PMC6743065).

7. Anatomical Structures Affected

Organ level: - Primary: Heart (myocardium — both ventricles); central nervous system/brain (encephalopathic component) - Secondary: Skeletal muscle (hypotonia/weakness); broader multisystem involvement typical of mitochondrial disease - Body systems: Cardiovascular system (primary); nervous system (primary — "encephalo-"); musculoskeletal system (hypotonia); metabolic/endocrine (lactic acidosis) - UBERON: heart (UBERON:0000948); brain (UBERON:0000955); skeletal muscle tissue (UBERON:0001134)

Tissue and cell level: - Myocardial tissue — both ventricles, with specific left ventricular non-compaction morphology - CL: cardiac muscle cell / cardiomyocyte (CL:0000746)

Subcellular level: - Mitochondria generally; specifically the mitochondrial intermembrane space (site of COA6 localization and function) and the mitochondrial inner membrane (site of complex IV/COX2 assembly) - GO Cellular Component: mitochondrial intermembrane space (GO:0005758); mitochondrial respiratory chain complex IV (GO:0045277)

Localization: Bilateral/systemic — biventricular cardiac hypertrophy (not lateralized); CNS involvement is generalized/encephalopathic rather than focal.

8. Temporal Development

• Onset: Congenital/neonatal — clinical features (hypotonia, systolic murmur, mild dysmorphism) present at birth, with severe lactic acidosis, hypothermia, and tachypnea developing "soon after birth."
• Onset pattern: Acute-to-subacute, rapidly evolving within the first days of life.
• Progression: Rapidly progressive to fatal cardiac and metabolic decompensation.
• Disease stages: No formal staging system exists (ultra-rare, no natural-history study); informally: (1) birth with subtle findings → (2) acute neonatal metabolic/cardiac crisis (lactic acidosis, hypothermia, tachypnea) → (3) progressive hypertrophic cardiomyopathy with LVNC and valvular regurgitation → (4) fatal cardiac/multiorgan failure in early infancy.
• Progression rate: Rapid — fatal course documented within the first weeks of life ("fatal course in the first weeks of life," per OMIM clinical synopsis).
• Disease course pattern: Progressive, non-remitting; no relapsing-remitting pattern described.
• Disease duration: Not self-limited — uniformly fatal in infancy in all reported cases to date.
• Remission: None reported; no spontaneous or treatment-induced remission documented for COA6 deficiency specifically (contrast with the unusual single case report of partial cardiac reversal with copper-histidine in SCO2 deficiency, PMID:14970747 — an analogous but genetically distinct disorder).
• Critical periods: The neonatal period itself is the critical window — given the rapidity of decompensation, any intervention (e.g., experimental copper therapy) would need to be initiated essentially at or before symptom onset to have a plausible chance of benefit, though this remains theoretical for COA6 specifically.

9. Inheritance and Population

Epidemiology: - Prevalence/incidence: Not formally estimated in any registry; this is an ultra-rare condition with only two independently ascertained, molecularly confirmed families published in the primary literature (Ghosh et al. 2014; Baertling et al. 2015), plus scattered additional ClinVar variant submissions. No population-based prevalence or incidence figures exist. For KB purposes this would be classified under prevalence_class: NOT_YET_DOCUMENTED or an ultra-rare qualitative band, given the case-report-level evidence base (fewer than 5 published, distinctly ascertained cases as of this search).

Inheritance pattern: Autosomal recessive (AR) — confirmed by compound heterozygosity in one family and homozygosity (with consanguineous parents) in the second. - HPO mode of inheritance: Autosomal recessive inheritance (HP:0000007)

Penetrance: Presumed complete/high penetrance given the severity and consistency of the phenotype across the (small number of) reported biallelic cases; formal penetrance estimates are not calculable from case-report-level data.

Expressivity: Appears relatively consistent (severe, neonatal-onset, cardiac-predominant) across the two published families, though the specific variant (missense mistargeting vs. compound het with a null allele) may plausibly affect severity/tissue-specificity nuances — insufficient data to formally characterize variable expressivity.

Genetic anticipation: Not applicable — this is not a repeat-expansion or anticipation-prone disorder.

Germline mosaicism: Not reported for COA6.

Founder effects: Not established; the two published pathogenic missense variants (W59C, W66R) and the nonsense variant (E87X) each occurred in unrelated/distinct families without evidence yet compiled for a specific population founder effect, though the consanguineous "Arab descent" family raises the possibility that region-specific carrier screening could be informative in populations with high consanguinity rates — this has not been formally studied.

Consanguinity role: Directly documented as relevant in the second reported family (homozygous W66R in a consanguineous Arab-descent family), consistent with the general pattern for ultra-rare autosomal recessive disorders.

Carrier frequency: Not established in the literature retrieved; gnomAD-based carrier-frequency estimation would need to be performed directly against the gnomAD browser for a KB entry (not confirmed in this search).

Population demographics: - Affected populations: Insufficient case numbers to identify ethnic/demographic enrichment beyond the documented consanguineous Arab-descent family. - Geographic distribution: No geographic clustering established; cases reported from at least two distinct, unrelated ascertainments (implying no single-population restriction, though sample size is far too small to draw firm conclusions). - Sex ratio: The two published index cases comprise one male infant (Ghosh et al.) and one female infant (Baertling et al.) — consistent with expected 1:1 autosomal recessive inheritance, not X-linked. - Age distribution: Exclusively neonatal/early infantile in all reported cases; no juvenile-, adult-, or late-onset COA6 phenotype has been published.

10. Diagnostics

Clinical/laboratory tests: - Serum lactate — elevated, reflecting lactic acidosis; LOINC-codable analyte. - Respiratory chain enzymology (muscle or fibroblast biopsy) — demonstrates isolated complex IV (cytochrome c oxidase) deficiency, with relatively preserved activity of other OXPHOS complexes — the classic biochemical signature directing genetic workup toward the COX-assembly-factor gene panel. - Echocardiography — primary imaging modality; shows biventricular hypertrophic cardiomyopathy with regional left ventricular non-compaction and valvular (mitral, tricuspid, pulmonic) regurgitation.

Genetic testing: - Whole-exome sequencing (WES) was the diagnostic modality used in both published families (trio-based approach identifying compound heterozygous or homozygous COA6 variants), consistent with the standard modern diagnostic pathway for suspected isolated mitochondrial complex IV deficiency in a neonate, given the large number of candidate nuclear COX-assembly genes. - Gene panel testing for "Nuclear Mitochondrial Disorders" (e.g., commercial panels such as Invitae's Nuclear Mitochondrial Disorders Panel) include COA6 as a covered gene. - Single-gene Sanger sequencing was used for confirmation/segregation analysis in both families following variant identification. - Muscle/fibroblast biopsy with biochemical complex IV assay and immunoblotting for COA6, COX2, SCO1, SCO2 protein levels — used as functional confirmation in both published cases (showing absent/reduced COA6 protein and reduced complex IV assembly).

Differential diagnosis: Other genetic causes of isolated/severe complex IV deficiency with cardiomyopathy, most importantly: - SCO2-related cardioencephalomyopathy — the closest biochemical/mechanistic relative (shares the copper-relay pathway with COA6; "links two mitochondrial cardiomyopathies," per Pacheu-Grau et al.) - SCO1-related hepatoencephalopathy/COX deficiency - COX15, COX10, SURF1, COA5, COA7, COX16, COX20 and other nuclear COX-assembly-factor genes causing overlapping fatal infantile cardioencephalomyopathy/COX-deficiency phenotypes (e.g., a 2021 report of a novel COX16 variant causing "severe fatal neonatal lactic acidosis, encephalopathy, cardiomyopathy, and liver dysfunction," Wintjes et al. 2021, Human Mutation) - Other causes of neonatal hypertrophic cardiomyopathy: sarcomeric gene defects (e.g., MYBPC3 compound heterozygous truncating variants causing fatal neonatal HCM), Noonan-spectrum RASopathies, glycogen storage disease (Pompe disease), Barth syndrome (TAZ, associated with LVNC specifically).

Screening: No specific newborn screening test exists for COA6 deficiency (not amenable to standard metabolic newborn screening panels); diagnosis relies on clinical suspicion in a neonate with unexplained hypertrophic cardiomyopathy plus lactic acidosis, triggering biochemical and genetic workup.

11. Outcome/Prognosis

• Survival/mortality: Uniformly fatal in early infancy in both published cases — described as a disorder with "a fatal course in the first weeks of life" (OMIM clinical synopsis for MC4DN13). No long-term survivors have been reported in the primary literature retrieved.
• Life expectancy: Days to a few weeks from birth, based on the two published cases.
• Complications: Progressive hypertrophic cardiomyopathy leading to cardiac pump failure; severe refractory lactic acidosis; hypotonia/weakness contributing to respiratory compromise.
• Recovery potential: None described in COA6-specific cases; contrast with the single reported case of partial, transient hypertrophic cardiomyopathy reversal in a SCO2-deficient patient treated with subcutaneous copper-histidine (PMID:14970747) — this is a mechanistically related but genetically distinct disorder, and no equivalent reversal has been reported for COA6.
• Prognostic factors: Severity of cardiac hypertrophy/non-compaction and degree of lactic acidosis at presentation appear to correlate with the uniformly poor outcome across the small case series; insufficient data to formally identify prognostic biomarkers.

12. Treatment

No disease-modifying or curative therapy exists for COA6-related fatal infantile cardioencephalomyopathy. Management to date has been supportive/palliative given the rapidly fatal neonatal course.

Pharmacotherapy — investigational/mechanistic rationale (cell-based, not yet clinically validated for COA6): - Copper supplementation: In vitro studies on patient fibroblasts are the strongest treatment-relevant finding in the literature: "Copper supplementation restores cytochrome c oxidase assembly defect in a mitochondrial disease model of COA6 deficiency" (Ghosh et al. 2014, Human Molecular Genetics, PMID:24549041) — "treatment of patient fibroblasts with copper led to a stable increase of complex IV and its subunits, suggesting a possible therapeutic option." This has been replicated at the cell-biology level but has not been reported as a clinical intervention in an actual COA6 patient (unlike the analogous SCO2 case, PMID:14970747, where subcutaneous copper-histidine was administered to a living patient with transient cardiac benefit). - NCIT candidate term: NCIT:C15986 (Pharmacotherapy); therapeutic_agent: copper (CHEBI, elemental/ionic copper — specific CHEBI ID would need verification, e.g., copper(II) chloride or copper-histidine complex depending on formulation) - Bezafibrate + copper combination (studied in SCO2 cellular models, not COA6 directly) achieved more complete rescue of COX activity than copper alone in related-gene cell models, suggesting a plausible but untested combination approach for COA6. - Elesclomol has been explored as a copper-ionophore restoring mitochondrial function in genetic models of copper deficiency broadly (PNAS, PMID not retrieved directly) — a theoretical, unvalidated-for-COA6 avenue.

Supportive/rehabilitative care: - Supportive care — symptom management, nutritional support, and cardiac supportive management (e.g., diuretics, inotropic support as clinically indicated) in the acute neonatal setting, though no COA6-specific treatment protocol has been published. - NCIT: NCIT:C15747 (Supportive Care)

Advanced/experimental therapeutics: No gene therapy, cell therapy, or RNA-based therapeutic approach has been reported for COA6-related disease specifically. No registered clinical trials (ClinicalTrials.gov) targeting COA6 deficiency were identified in this search.

Genetic counseling: Recommended for families of affected infants given confirmed autosomal recessive inheritance, with 25% recurrence risk per pregnancy for parents of an affected child; prenatal diagnosis via chorionic villus sampling/amniocentesis for known familial variants would be technically feasible once the causative variants are identified in a family, though no specific published experience with prenatal diagnosis for COA6 was found. - NCIT: NCIT:C15240 (Genetic Counseling)

Treatment outcomes: No systematic treatment-response, side-effect, or adverse-event data exist for COA6-directed therapy in humans, since no clinical (as opposed to cell-culture) therapeutic intervention has been reported.

13. Prevention

• Primary prevention: Genetic counseling and carrier testing in families with a known affected child or in populations with elevated consanguinity, to inform reproductive decision-making. No population-level primary prevention program exists given the extreme rarity of the condition.
• Secondary prevention/screening: Prenatal genetic testing (once familial variants are known) and/or preimplantation genetic diagnosis (PGD) are theoretically applicable standard approaches for a known autosomal recessive lethal disorder, though no published experience specific to COA6 was identified.
• Tertiary prevention: Not applicable in the classic sense, given the rapidly fatal neonatal course precludes long-term complication management; acute supportive cardiac/metabolic management in the immediate neonatal period represents the only available "tertiary" intervention window.
• Immunization: Not applicable — no infectious/immune component to this disease.
• Public health/environmental interventions: Not applicable — purely monogenic disorder with no environmental prevention target.
• Prophylaxis: None established; investigational copper supplementation (see Treatment) has not been validated as prophylactic therapy in at-risk newborns (e.g., a sibling known to carry the familial genotype prenatally) and is not standard of care.

14. Other Species / Natural Disease

• Taxonomy: No naturally occurring veterinary/companion-animal disease caused by spontaneous COA6 mutation has been reported in this search (contrast with many other mitochondrial disease genes that have recognized veterinary analogs); COA6 biology has been studied primarily through engineered/induced models (yeast complementation, zebrafish morpholino knockdown) rather than naturally occurring animal disease.
• Orthologous gene: Yeast Ymr244c-a/COA6 ortholog (used for functional complementation studies); zebrafish coa6 ortholog (used for morphant knockdown cardiac phenotyping); mouse Coa6 ortholog, MGI:1915142, located on an autosome in mouse, with entries in IMPC and MGI — a systematic knockout-phenotype dataset exists at IMPC, though detailed cardiac-specific phenotype results were not extracted in this search and should be checked directly at the IMPC gene page for a KB animal_models entry.
• Comparative biology: COA6 function (thiol-reductase-mediated copper delivery to COX2 for complex IV assembly) is deeply evolutionarily conserved from yeast to zebrafish to humans — demonstrated directly by the cross-species complementation and knockdown experiments in the founding Ghosh et al. 2014 paper, which used "an integrative approach based on clues from evolutionary history, protein localization and human genetics" spanning all three systems.
• Zoonotic potential/cross-species susceptibility: Not applicable — this is a cell-autonomous, non-infectious, genetically determined mitochondrial disorder.

15. Model Organisms

Yeast (Saccharomyces cerevisiae): - Model type: Cellular/unicellular eukaryotic model. - Coa6-null yeast strain used for functional complementation assays: wild-type human COA6 rescues the respiratory growth defect of Coa6-null yeast, while patient-derived mutant alleles (W59C, E87X, W66R) fail to rescue, directly demonstrating loss-of-function pathogenicity (Ghosh et al. 2014, PMID:24549041). - Application: Structure-function dissection of the conserved CX9CXnCX10C cysteine motif; rapid, genetically tractable system for variant-effect functional validation. - Resource: SGD - Saccharomyces Genome Database entry

Zebrafish (Danio rerio): - Model type:* Vertebrate, induced (morpholino knockdown) model. - coa6 knockdown (morphant) zebrafish embryos display reduced heart rate and cardiac developmental defects, "recapitulating the observed pathology in the human mitochondrial disease patient who died of neonatal hypertrophic cardiomyopathy" (Ghosh et al. 2014). - Phenotype recapitulation: High-fidelity for the cardiac/developmental phenotype at a gross morphological/functional level (heart rate, cardiac structure); the conserved residue corresponding to the human patient mutation was shown to be essential for COA6 function in this system, directly supporting pathogenicity of the human variant. - Limitations: Morpholino knockdown (rather than a stable genetic knockout/knock-in mutant line) has inherent limitations (potential off-target/incomplete knockdown effects, transient embryonic-stage-only assessment) — this should be recorded as a fidelity: MODERATE or similar caveat if curated as a modeled_mechanisms link, with limitations noting the morpholino (vs. genetic mutant) nature of the model. - Resource:* ZFIN (zebrafish model organism database) — specific ZFIN accession not retrieved in this search.

Mouse (Mus musculus): - Model type: Mammalian, genetic (knockout) model — via the International Mouse Phenotyping Consortium. - Gene: Coa6, MGI:1915142. - Resource: IMPC gene page and MGI marker page — systematic phenotyping data are cataloged there; specific cardiac/lethality phenotype results were not extracted in this search pass and should be directly reviewed before KB curation (IMPC knockout-mouse embryonic lethality is common for essential mitochondrial assembly-factor genes and would be an important data point to confirm/record).

Human cell-based models: - Patient-derived fibroblasts (from both published families) — the primary human cellular model, used for: complex IV enzymatic activity assays, COA6/COX2/SCO1/SCO2 immunoblotting, and copper-supplementation rescue experiments. - HEK293/HeLa cell overexpression and knockdown/knockout systems — used extensively in the mechanistic follow-up literature (Pacheu-Grau et al. 2015; Soma et al. 2019; structural biology papers) to dissect the COA6–SCO1–SCO2–COX2–COX20–TMEM177 interaction network.

Research applications enabled by these models: Variant-effect functional classification (yeast complementation); cardiac developmental phenotyping (zebrafish); systemic/embryonic phenotyping and potential lethality assessment (mouse knockout, via IMPC); detailed biochemical/structural dissection of the copper-relay assembly pathway and therapeutic (copper supplementation) proof-of-concept (human fibroblasts and human cell lines).

Summary of Key Ontology Term Suggestions for KB Curation

Citation Requirements — Key Primary Literature

1. Ghosh A, Trivedi PP, Timbalia SA, Griffin AT, Rahn JJ, Chan SS, Gohil VM. "Copper supplementation restores cytochrome c oxidase assembly defect in a mitochondrial disease model of COA6 deficiency." Hum Mol Genet. 2014;23(13):3596-3606. PMID: 24549041
2. (Companion clinical report) "Mutations in COA6 cause cytochrome c oxidase deficiency and neonatal hypertrophic cardiomyopathy." PMID: 25339201
3. Baertling F, et al. (2015) — homozygous COA6 W66R in consanguineous family; described in OMIM #616501
4. Pacheu-Grau D, et al. "Cooperation between COA6 and SCO2 in COX2 Maturation during Cytochrome c Oxidase Assembly Links Two Mitochondrial Cardiomyopathies." Cell Metab. 2015;21(6):823-833. PMID: 25959673
5. "Mitochondrial disease genes COA6, COX6B and SCO2 have overlapping roles in COX2 biogenesis." PMID: 26669719
6. Soma S, et al. "COA6 Is Structurally Tuned to Function as a Thiol-Disulfide Oxidoreductase in Copper Delivery to Mitochondrial Cytochrome c Oxidase." Cell Rep. 2019;29(12):4114-4126. PMID: 31851937
7. "COA6 Facilitates Cytochrome c Oxidase Biogenesis as Thiol-reductase for Copper Metallochaperones in Mitochondria." PMID: 32061935
8. Structural/functional characterization: "Structural and functional characterization of the mitochondrial complex IV assembly factor Coa6." Life Sci Alliance. 2019. PMC: PMC6743065
9. "The Role of COA6 in the Mitochondrial Copper Delivery Pathway to Cytochrome c Oxidase." PMC: PMC8773535
10. OMIM #616501 — Mitochondrial Complex IV Deficiency, Nuclear Type 13: omim.org/entry/616501
11. OMIM *614772 — COA6 gene: omim.org/entry/614772
12. Orphanet gene page: orpha.net/en/disease/gene/COA6
13. Reference (analogous SCO2 copper therapy case): "Reversion of hypertrophic cardiomyopathy in a patient with deficiency of the mitochondrial copper binding protein Sco2." PMID: 14970747

Note on evidence completeness for KB curation: This report was assembled from web search and fetched summaries rather than full-text verbatim abstract retrieval for every source (several PubMed/OMIM pages returned cookie-consent/403 blocks rather than raw text during this session). Before entering any snippet: evidence field into the dismech KB, each citation above must be independently re-fetched via just fetch-reference <PMID> and the exact quoted text verified against the cached abstract/full text, per the project's evidence-integrity requirements — none of the quotations reproduced above should be treated as pre-verified exact-source substrings.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:25959673 (abstract only): "Cooperation between COA6 and SCO2 in COX2 Maturation... Links Two Mitochondrial Cardiomyopathies"
• closest text in source: "Our analyses define COA6 as a constituent of the mitochondrial copper relay system, linking defects in COX2 metallation to cardiac cytochrome c oxidase deficiency."

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0014668 (3 mentions) - the report calls it "if available", "Disease"; MONDO calls it cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4
• HP:0006955 (2 mentions) - the report calls it "HPO: Left ventricular noncompaction cardiomyopathy", "Left ventricular noncompaction cardiomyopathy"; HP calls it Olivopontocerebellar hypoplasia**
• HP:0031628 (2 mentions) - the report calls it "HPO: Mitral regurgitation", "Mitral regurgitation"; HP calls it Aborted sudden cardiac death**

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• HP:0001725 (1 mention) - HP does not contain this term

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0001639 (2 mentions) - the report calls it "HPO: Hypertrophic cardiomyopathy", "Hypertrophic cardiomyopathy"; HP calls it Hypertrophic cardiomyopathy**
• HP:0003128 (2 mentions) - the report calls it "HPO: Lactic acidosis", "Lactic acidosis"; HP calls it Lactic acidosis**
• HP:0002045 (2 mentions) - the report calls it "HPO: Hypothermia", "Hypothermia"; HP calls it Hypothermia**
• HP:0001252 (2 mentions) - the report calls it "HPO: Hypotonia"; HP calls it Hypotonia**
• HP:0001508 (2 mentions) - the report calls it "HPO: Failure to thrive", "Failure to thrive"; HP calls it Failure to thrive**
• HP:0001298 (1 mention) - the report calls it "HPO candidate terms: Encephalopathy"; HP calls it Encephalopathy**
• GO:0033617 (2 mentions) - the report calls it "GO: mitochondrial respiratory chain complex IV assembly", "mitochondrial respiratory chain complex IV assembly"; GO calls it mitochondrial respiratory chain complex IV assembly**
• CL:0000746 (3 mentions) - the report calls it "Cell types affected: cardiomyocyte", "CL: cardiac muscle cell / cardiomyocyte", "cardiac muscle cell"; CL calls it cardiac muscle cell, and lists "cardiomyocyte" among its other names
• GO:0005758 (3 mentions) - the report calls it "GO Cellular Component: mitochondrial intermembrane space", "mitochondrial intermembrane space"; GO calls it mitochondrial intermembrane space**
• UBERON:0000948 (2 mentions) - the report calls it "UBERON: heart"; UBERON calls it heart**, and lists "chambered heart" among its other names
• GO:0045277 (2 mentions) - the report calls it "mitochondrial respiratory chain complex IV"; GO calls it respiratory chain complex IV
• HP:0000007 (2 mentions) - the report calls it "HPO mode of inheritance: Autosomal recessive inheritance", "Autosomal recessive inheritance"; HP calls it Autosomal recessive inheritance**

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• MONDO:0014668 - called "if available", "Disease"
• HP:0001639 - called "HPO: **Hypertrophic cardiomyopathy", "Hypertrophic cardiomyopathy"
• HP:0006955 - called "HPO: **Left ventricular noncompaction cardiomyopathy", "Left ventricular noncompaction cardiomyopathy"
• HP:0031628 - called "HPO: **Mitral regurgitation", "Mitral regurgitation"
• HP:0003128 - called "HPO: **Lactic acidosis", "Lactic acidosis"
• HP:0002045 - called "HPO: **Hypothermia", "Hypothermia"
• HP:0001508 - called "HPO: **Failure to thrive", "Failure to thrive"
• GO:0033617 - called "GO: **mitochondrial respiratory chain complex IV assembly", "mitochondrial respiratory chain complex IV assembly"
• CL:0000746 - called "Cell types affected: cardiomyocyte", "CL: cardiac muscle cell / cardiomyocyte", "cardiac muscle cell"
• GO:0005758 - called "GO Cellular Component: **mitochondrial intermembrane space", "mitochondrial intermembrane space"
• HP:0000007 - called "HPO mode of inheritance: **Autosomal recessive inheritance", "Autosomal recessive inheritance"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI.